Outstanding Clinical Evaluation Results from Saudi Arabia

NZX/ASX Announcement 14 March 2023 Outstanding Clinical Evaluation Results from Saudi Arabia Highlights o First clinical evaluation completed in the Middle East o Results show sensitivity and specificity better than or close to Liquid Based Cytology testing Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that the leading private medical services provider , Dr. Sulaiman Al-Habib Medical Group (DSAMG), has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC). A cohort of 507 women were examined with TruScreen and LBC across multiple medical centres of DSAMG. The preliminary results confirmed that TruScreen's sensitivity was 83.3% (LBC: 66%) and specificity was 95% (LBC 98%). Lead investigator Dr. Majed Alhudhud, Head of OBGYN Department at Arryan Hospital, said "There is no national program for cervical cancer screening in Saudi Arabia, and we see TruScreen as a strong alternative to the standard LBC. In the study we found TruScreen to be as effective as LBC, while also providing real time results and resolving many of the issues faced with potential patient follow-up when using LBC." TruScreen's CEO, Dr Beata Edling commented, "We are delighted with the results of our first clinical evaluation in Saudi Arabia and the Middle East. It validated clinical evaluations conducted in China. Australia, and Vietnam. We looked forward to enhanced women's health care in Saudi Arabia and to the neighbouring Gulf countries. TruScreen is represented in this region, by our distributor, BettaLife Group". This announcement has been approved by the Board. Ends For more information, visit www.truscreen.com or contact: Dr Beata Edling Chief Executive Officer beataedling@truscreen.com Guy Robertson Chief Financial Officer guyrobertson@truscreen.com Julia Maguire Investor Relations julia@thecapitalnetwork.com.au End CA:00408275 For:TRU Type:GENERAL Time:2023-03-14 09:13:47